These three peptides account for most of what people are asking about, and most of what is written about them online is either promotional or out of date. Here is where they actually stand, with the date attached, because this area is moving.
Regulatory status — current as of August 2026
None of these compounds is FDA-approved for any use. BPC-157, CJC-1295 and thymosin beta-4 (TB-500) were nominated for the FDA’s 503A Bulks List and are no longer in Category 2 — the nominations were withdrawn before evaluation was completed, and the FDA’s April 2026 listing places them in its withdrawn table. On 23 July 2026 the FDA’s Pharmacy Compounding Advisory Committee proposed that TB-500 not be added to the Bulks List at all.
That last development is being reported in some places as though the restriction has lifted. It has not. Removal from Category 2 is not authorisation. Under section 503A, a bulk substance generally needs a USP monograph, or to be a component of an FDA-approved drug, or a place on the 503A Bulks List, before it can be compounded from bulk. None of these three has any of the three. A withdrawn nomination means the safety question was never resolved — not that it was resolved in the compound’s favour.
If a clinic tells you these are now cleared, ask them which of those three conditions they believe is met.
BPC-157
A synthetic fragment derived from a protein found in gastric juice. The preclinical literature on tendon, ligament and gut healing is genuinely extensive and consistently positive — in rodents. Controlled human trials establishing those effects have not been published. The FDA has cited an absence of human safety data. What exists is a large animal literature and a large volume of anecdote, and those are not the same thing as evidence in people.
TB-500 (thymosin beta-4 fragment)
A synthetic fragment of thymosin beta-4, marketed for tissue repair. The FDA has flagged the potential for immune reactions, and in its July 2026 review noted the substance is not physically and chemically well characterised — meaning what is in a given vial is harder to establish than for a better-defined compound. It is prohibited in sport by WADA. Human efficacy data for the marketed uses is essentially absent.
CJC-1295
A growth-hormone-releasing hormone analogue, usually marketed alongside ipamorelin to raise endogenous growth hormone. The mechanism is real and measurable — it does raise GH and IGF-1. Whether that produces the outcomes it is sold for, in healthy adults, over time, has not been established, and raising growth hormone is not a benign intervention to undertake without a clear indication. Note that ipamorelin, its usual pairing, is currently on the FDA’s Category 2 list for 503B compounding.
What this page does not include
No doses, no cycles, no administration instructions and no sourcing. Those were on this page previously and have been removed. For an unapproved compound with no established human safety profile, publishing a protocol implies a confidence that does not exist, and the dose is a conversation with a prescriber who is taking responsibility for it.
What Venturis Clinic provides
Venturis Clinic does not provide peptide therapy. It is available through Alpha Men’s Clinic, a separate telehealth practice. Dr. Philipose retains a financial interest in Alpha Men’s Clinic.
For the wider evidence picture see what the human research shows; for choosing a provider, see the seven questions worth asking first.
This page is educational and is not medical advice. Regulatory status is current as of August 2026 and is subject to change. Reviewed by Alvin Philipose, DC, ICCP · Last reviewed August 2026.
